Retour
Cypherpunk Technologies Inc. (LPTX) Gagner
Graphique du cours de l'action LPTX
LPTX Gagner
Cypherpunk Technologies Inc.
$0.69
19.01%
$0.11
À partir d'aujourd'hui :Mar 24, 13:26:50 GMT-4
Pas encore de donnéesEarnings FAQ
Comment le bénéfice par action récent de LPTX se compare-t-il aux attentes ?
Comment les revenus de Cypherpunk Technologies Inc. LPTX se sont-ils comportés au dernier trimestre ?
Quelle est l'estimation des revenus pour Cypherpunk Technologies Inc. ?
Quel est le score de qualité des bénéfices pour Cypherpunk Technologies Inc. ?
Quand Cypherpunk Technologies Inc. publie-t-elle ses résultats ?
Quels sont les bénéfices attendus de Cypherpunk Technologies Inc. ?
Cypherpunk Technologies Inc. a-t-elle dépassé les attentes en matière de bénéfices ?
Statistiques clés
Clôture préc.
$0.58
Prix d'ouverture
$0.64
Plage de la journée
$0.61 - $0.6949
Plage de 52 semaines
$0.2223 - $3.69
Volume
174.5K
Volume moyen
21.9M
Rendement en dividend
--
BPA (TTM)
-1.58
Capitalisation boursière
$39.1M
Qu’est-ce que Leap Therapeutics, Inc. ?
Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2017-01-24. The firm is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The firm is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The firm also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Fonctionnalités
Ressources
© 2026 Finture Development Limited. Tous droits réservés.